311 related articles for article (PubMed ID: 18785896)
1. Tolterodine immediate release improves sexual function in women with overactive bladder.
Hajebrahimi S; Azaripour A; Sadeghi-Bazargani H
J Sex Med; 2008 Dec; 5(12):2880-5. PubMed ID: 18785896
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
5. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women.
Rogers R; Bachmann G; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Nov; 19(11):1551-7. PubMed ID: 18685795
[TBL] [Abstract][Full Text] [Related]
9. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
11. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
13. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
Roberts RG; Garely AD; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
[TBL] [Abstract][Full Text] [Related]
15. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
16. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
[TBL] [Abstract][Full Text] [Related]
17. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
18. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
[TBL] [Abstract][Full Text] [Related]
19. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
20. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
